News

September 23, 2024

AffyImmune Appoints Drs. Rick Rutter and Jorge Nieva to Board of Directors

July 23, 2024

AffyImmune Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for AIC100 in Recurrent Anaplastic Thyroid Cancer

July 15, 2024

AffyImmune Appoints Dr. Daniel Janse as Chief Executive Officer

May 23, 2024

AffyImmune Announces Confirmed Complete Response in Patient with Anaplastic Thyroid Cancer

April 24, 2024

AffyImmune Announces Presentation on Affinity-Tuned CAR T Therapy AIC100 at ASCO 2024

April 9, 2024

AffyImmune Presents Preclinical Data on AIC100 Affinity-Tuned CAR T Targeting ICAM-1 in Additional Solid Tumor Types at AACR 2024